Business Wire

China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gilead’s Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection

Del

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China Drug Administration (CDA) has approved Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. The CDA also approved Epclusa in combination with ribavirin (RBV) for adults with HCV and decompensated cirrhosis. Epclusa is the first pan-genotypic HCV single tablet regimen (STR) approved in China.

The approval of Epclusa in China is supported by five international Phase 3 studies, ASTRAL-1, ASTRAL-2, ASTRAL-3, ASTRAL-4 and ASTRAL-5. High overall rates of SVR12 (defined as undetectable HCV RNA 12 weeks after completing therapy), ranging from 92-100 percent, were achieved across difficult-to-cure patient populations including treatment-experienced patients and those with compensated or decompensated cirrhosis.

“The safety and efficacy profile of Epclusa are supported by large clinical and real-world global datasets,” said Professor Lai Wei, Peking University People’s Hospital and Institute of Hepatology, Peking University. “With high cure rates across all HCV genotypes, Epclusa could increase HCV treatment in China by potentially eliminating the need for genotype testing, which can be a barrier to treatment in many settings.”

HCV is the fourth-most commonly reported infectious disease in China, with approximately 10 million people infected. HCV genotypes 1, 2, 3 and 6 account for more than 96 percent of all cases.

In the ASTRAL-1, ASTRAL-2 and ASTRAL-3 studies, 1,035 treatment-naïve and treatment-experienced patients with genotype 1-6 HCV infection, without cirrhosis or with compensated cirrhosis, received 12 weeks of Epclusa. Ninety-eight percent (1,015/1,035) of patients achieved SVR12. In the ASTRAL-5 study, 106 treatment-naïve and treatment-experienced patients with genotype 1-6 HCV infection, without cirrhosis or with compensated cirrhosis, who were coinfected with HIV and on a stable antiretroviral therapy, received 12 weeks of Epclusa. Ninety-five percent (101/106) of patients achieved SVR12.

The ASTRAL-4 study assessed the safety and efficacy of 12 weeks of Epclusa with or without RBV or 24 weeks of Epclusa in 267 HCV-infected patients with genotypes 1-4 and 6 decompensated cirrhosis (Child-Pugh B). Patients with decompensated cirrhosis receiving Epclusa with RBV for 12 weeks achieved 94 percent (82/87) SVR12.

The most common adverse reactions (≥10 percent) experienced by patients treated with Epclusa in ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-5 were headache and fatigue. The placebo-treated patients in the ASTRAL-1 experienced headache and fatigue at a similar frequency. The most common adverse reactions (≥10 percent) experienced by HCV-infected patients with decompensated cirrhosis treated with Epclusa and RBV in ASTRAL-4 were fatigue, anemia, nausea, headache, diarrhea and insomnia. Four patients treated with Epclusa with RBV, discontinued treatment due to adverse events.

“As the first once-daily, interferon-free single tablet regimen for HCV patients regardless of genotype, Epclusa offers physicians in China an important new option for effectively treating their patients while potentially helping to reduce the significant burden of HCV at a population level,” said John F. Milligan, PhD, Gilead’s President and Chief Executive Officer. “Gilead has now launched two direct-acting antiviral treatments in China, and we are committed to supporting efforts to screen and link patients to treatment, to help address the country’s HCV epidemic.”

Epclusa received marketing approval from the U.S. Food and Drug Administration (FDA) and the European Commission in 2016 as the first pan-genotypic STR for HCV infection. It is also approved for use in 54 countries.

Sovaldi (sofosbuvir) as a single agent received marketing approval from the China Food and Drug Administration in 2017 for the treatment of adults infected with HCV genotype 1, 2, 3, 4, 5 or 6 and for adolescents (aged 12 to 18 years) with HCV genotype 2 or 3, as a component of a combination antiviral treatment regimen.

IMPORTANT SAFETY INFORMATION AND INDICATION FOR EPCLUSA IN U.S.

BOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN HCV/HBV COINFECTED PATIENTS

Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in patients who are HBsAg positive, in patients with serologic evidence of resolved HBV, and also in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV DAAs may be increased in patients taking these other agents. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.

Contraindications

If EPCLUSA is used in combination with ribavirin (RBV), all contraindications, warnings and precautions, in particular pregnancy avoidance, and adverse reactions to RBV also apply. Refer to RBV prescribing information.

Warnings and Precautions

Serious Symptomatic Bradycardia When Coadministered with Amiodarone: Amiodarone is not recommended for use with EPCLUSA due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. A fatal cardiac arrest was reported in a patient taking amiodarone who was coadministered a sofosbuvir containing regimen. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.

Risk of Reduced Therapeutic Effect Due to Concomitant Use of EPCLUSA with P-gp Inducers and/or Moderate to Potent Inducers of CYP2B6, CYP2C8 or CYP3A4: Rifampin, St. John’s wort, and carbamazepine are not recommended for use with EPCLUSA as they may significantly decrease sofosbuvir and/or velpatasvir plasma concentrations.

Adverse Reactions

The most common adverse reactions (≥10%, all grades) with EPCLUSA were headache and fatigue; and when used with RBV in decompensated cirrhosis were fatigue, anemia, nausea, headache, insomnia, and diarrhea.

Drug Interactions

Coadministration of EPCLUSA is not recommended with topotecan due to increased concentrations of topotecan.

Coadministration of EPCLUSA is not recommended with proton-pump inhibitors, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifapentine, efavirenz, and tipranavir/ritonavir due to decreased concentrations of sofosbuvir and/or velpatasvir.

Consult the full Prescribing Information for EPCLUSA for more information on potentially significant drug interactions, including clinical comments.

Indication

EPCLUSA is indicated for the treatment of adults with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that physicians may not see the benefits of prescribing Epclusa. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

U.S. Full Prescribing Information for Epclusa and Sovaldi, including BOXED WARNING is available at www.gilead.com

Epclusa and Sovaldi are registered trademarks of Gilead Sciences, Inc., or its related companies.

For more information on Gilead Sciences, please visit the company’s website at  www.gilead.com , follow Gilead on Twitter ( @GileadSciences ) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contact information

Gilead Sciences, Inc.
Sung Lee, 650-524-7792 (Investors)
Sonia Choi, 650-425-5483 (Media)

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

TYAN Introduces Entry Server Platforms Optimized for the New Intel® Xeon® E-2100 Processors13.12.2018 13:00Pressemelding

TYAN®, an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, is releasing a broad selection of new server motherboards and systems optimized for the new Intel® Xeon® E-2100 processors. The new lineup is designed to offer enhanced performance, advanced security, and reliability of cost-effective entry server solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213005005/en/ TYAN's New Intel Xeon E-2100 Processor-based Platforms Increase Reliability and Security for Entry Servers. (Photo: Business Wire) “Small and medium-size businesses need to maintain their competitiveness by deploying a powerful server platform for performance, enhanced memory capabilities, and hardware-enhanced security,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “TYAN’s Intel® Xeon® E-2100 processor-based platforms are optimized for clou

GSMA’s Programme ‘Tech4Girls’ Wins 2018 Corporate Citizen of the Americas Award from the Organization of American States13.12.2018 13:00Pressemelding

The Trust for the Americas has selected GSMA as a winner of the 2018 Corporate Citizen of the Americas Award in the category ‘Technical Skills for the Future of Work’ for its program ‘Tech4Girls’. The award was presented by the Secretary General of the Organization of American States (OAS), Luis Almagro, at a ceremony held last week in Washington, D.C. Ana Tavares Lattibeaudiere, Head of North America, and Paula Ferrari, Regional Marketing Director for Latin America, received the award on behalf of the GSMA. Tech4Girls is part of the global GSMA’s Women4Tech programme, which focuses on reducing the persistent gender gap in the mobile industry. Women4Tech offers different touchpoints for women across their education and career journeys through dedicated initiatives, development and networking opportunities. Women4Tech supports the United Nations Sustainable Development Goals, in particular SDG 5: “Gender Equality.” Launched in March 2018 by GSMA North America, Tech4Girls delivers hands-

FLIR Systems Launches Three Cooled Neutrino Family Thermal Camera Cores13.12.2018 13:00Pressemelding

FLIR Systems, Inc. (NASDAQ: FLIR) today announced three Neutrino™ midwave infrared (MWIR) camera cores: the small, lightweight FLIR Neutrino LC and two FLIR Neutrino Performance series cores, the SX12 and QX. The latest models expand the FLIR Neutrino cooled camera core family for commercial, industrial, and defense original equipment manufacturers (OEM) and system integrators. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213005036/en/ Next generation cooled FLIR Neutrino thermal camera cores: Neutrino LC (left) and Neutrino Performance Series (right). (Photo: Business Wire) The Neutrino LC is FLIR’s first High Operating Temperature (HOT) MWIR camera core and the first model in the SWaP+C (Size, Weight, Power, and Cost) series. As the smallest, lightest weight, and lowest power consuming Neutrino model available, the LC can be integrated with smaller drones and allow drone operators to fly longer. With HOT technology, N

Biomax Informatics launches the NeuroXM™ Brain Science Suite13.12.2018 12:57Pressemelding

Biomax Informatics AG announced the launch of its latest product, the NeuroXM™ Brain Science Suite, this week at the Biomax-ETRI Symposium on Cognitive Brain Informatics held in Planegg, Germany. Following a successful early-adaptor program, the company launched the NeuroXM suite of tools and features for working with multimodal high-dimensional brain data ready for clinical use. The award-winning NeuroXM Brain Science Suite lets brain scientists work interactively with high-dimensional multimodal brain data ranging from neuroimaging to genetics and transcriptomics. The suite includes a unified knowledge model for managing the abundant heterogeneous data available for the brain. It connects patient brain data to public knowledge in databases, atlases and ontologies for automatic annotation with methodological meta-information so that they become invaluable for clinical and scientific use. The NeuroXM suite supports every brain science task from standardizing preprocessing workflows to

Slice Insurance Cloud Services Now Available in the UK & EU13.12.2018 12:00Pressemelding

Slice Labs Inc., an award-winning on-demand insurance cloud platform provider, announced today the availability of Insurance Cloud Services (ICS) in the UK and EU. The first customer to use ICS in the UK is Legal & General with the launch of on-demand, pay-per-use homeshare cover. Insurance products available through the Slice ICS platform offer customers a rich, engaging, fully digital experience that is quick, and flexible. True to the company’s stated intention of extending global availability of ICS following a $20M USD Extended Series A, UK and EU insurers are now able to subscribe to ICS and launch on-demand insurance products customised to locale, language, and demographics. Cheryl Agius, CEO of Legal & General’s Insurance division, said “Legal & General is delighted to be working with Slice on the new on-demand product, a growing business in the US and now in the UK market.” European insurtech influencer Dr. Robin Kiera, CEO of DigitalScouting added, “Digital transformation lea

Western Union Works with TerraPay to Expand Payout Options to Millions of Mobile Wallets13.12.2018 12:00Pressemelding

Western Union (NYSE: WU), a leader in cross-border, cross-currency money movement, announces an alliance with TerraPay to enable mobile wallet and bank account payout. The alliance further expands upon Western Union’s account payout network for sending remittances directly into customers’ mobile wallets across Europe, Africa, Asia and Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213005331/en/ TerraPay CEO Ambar Sur and Head of Account Payout Network for Western Union Sobia Rahman (Photo: Business Wire) TerraPay’s low value payments network connects financial instruments internationally. The company’s interoperability engine enables customers to send and receive transactions across diverse payment instruments and platforms – enabling mobile wallets in international, regional and domestic markets. “Joining with TerraPay is a great opportunity to further diversify and expand our payment options across the gl